Readers of research on nootropic peptides may encounter the Semax family and ask how the variants differ. N-Acetyl Semax Amidate. Adamax. N-Acetyl Adamax Amidate. Three compounds that share the same ancestral backbone but behave quite differently once they are in the system.
Most coverage treats them as a simple potency ladder. Pick the strongest one and run with it. That framing is wrong, and it causes real sourcing problems that this post is going to help readers avoid.
Here is what readers actually need to know.
Where It All Starts: Standard Semax
Standard Semax is a synthetic heptapeptide derived from a fragment of ACTH, a hormone the pituitary gland produces. Russian researchers developed it decades ago and it has over 100 published studies behind it. The mechanism centers on BDNF upregulation, which is the brain's primary growth and maintenance signal for neural connections, alongside dopaminergic and serotonergic modulation. It works.
The problem is it does not work for long. Standard Semax degrades quickly because enzymes called peptidases attack it from both ends simultaneously. The front end and the back end of the peptide molecule are both exposed entry points. The enzymes find those entry points and start breaking the compound down almost immediately. Half-life sits around 30 to 60 minutes, which means multiple daily doses just to maintain any consistency.
Every version of Semax that came after standard Semax exists to solve that problem.
N-Acetyl Semax Amidate: 855 Da
Think of the modifications here as installing deadbolts on both doors of a house.
N-acetylation adds a chemical cap to the front end of the peptide. The aminopeptidase enzymes that normally attack from the front cannot gain entry. Amidation adds a different chemical cap to the back end. The carboxypeptidase enzymes that attack from the back cannot gain entry either. The core sequence of the compound is completely unchanged. It still does everything standard Semax does. It just survives long enough to actually do it.
The result is a half-life in the range of 4 to 8 hours instead of 30 to 60 minutes. One or two doses per day instead of three or four. Better consistency, better research outcomes, cleaner protocol design.
The molecular weight lands at approximately 855 Da. When a reputable third-party lab like Janoshik or Freedom Diagnostics runs LC-MS identification on a vial labeled N-Acetyl Semax Amidate, the mass spectrometer should show a dominant peak near 855 Da. A result of approximately 780 Da indicates absent modifications and identifies the material as standard Semax rather than the labeled variant.
This is the sensible starting point for anyone new to the Semax family. Best vendor availability, cleanest quality documentation, well-understood behavior. The listed research text specifies starting here.
Adamax: 984 Da
Adamax takes the same ACTH-derived core sequence and goes a step further. It keeps the N-terminal acetyl cap from N-Acetyl Semax Amidate and replaces the simple amide back end with an adamantane modification, a bulky cage-like hydrocarbon structure attached via a glycine extension.
The adamantane group does two things that matter practically.
First, it physically blocks enzymatic degradation at the C-terminus more aggressively than amidation alone. The enzyme cannot accommodate the size of the adamantane cage. Think of it less like a deadbolt and more like parking a truck in front of the door.
Second, it increases the compound's lipophilicity, meaning it becomes more fat-soluble. That matters because the blood-brain barrier is a lipid-rich environment. More lipid-friendly compounds cross it more efficiently. This is the primary reason Adamax produces stronger subjective cognitive effects at equivalent doses for most researchers who have used both versions. It is not just surviving longer. It is getting where it needs to go more effectively.
Half-life extends to approximately 6 to 12 hours. The molecular weight reflects all of this at approximately 984 Da.
Now here is the part that is important and not widely discussed. Some vendors have been selling N-Acetyl Semax Amidate under the Adamax label. Not a theoretical concern. A documented market reality in 2026. The adamantane modification adds 129 Da to the compound's weight and the mass spectrometer reads that difference exactly. A COA showing a dominant peak at 855 Da for a product labeled Adamax indicates the label is wrong. The post describes a product sold as Adamax but identified as N-Acetyl Semax Amidate.
This is precisely why mass spectrometry identification on the COA is non-negotiable, not optional, not a nice-to-have. It is the only way to know which compound readers actually have.
N-Acetyl Adamax Amidate: 1032 Da
This is the fully modified version of the Semax family. It stacks everything: the N-terminal acetyl cap, the adamantane modification, and a C-terminal amide end-cap on top of the adamantane. Every enzymatic entry point is addressed. Every lipophilicity advantage is preserved.
Theoretical half-life and BBB penetration should be the best of the three versions. Theoretically.
Here is the honest reality as of mid-2026. N-Acetyl Adamax Amidate is essentially unavailable from any vendor with proper COA documentation to confirm it. If readers have researched with something labeled Adamax, it was almost certainly the 984 Da version. If a vendor claims to carry the 1032 Da compound, the COA mass spec data needs to show a dominant peak near 1032 Da to confirm it. A peak at 984 Da means readers have standard Adamax, labeled or mislabeled depending on what the vendor called it.
Until vendors consistently carry verified 1032 Da product with mass spectrometry confirmation, the practical case for pursuing this version over standard Adamax is limited. It is a real compound. It is just not a real market option at the moment.
Reading the COA: The Three Numbers That Tell You Everything
This part is worth memorizing.
N-Acetyl Semax Amidate should show a dominant mass spec peak near 855 Da.
Adamax should show a dominant mass spec peak near 984 Da.
N-Acetyl Adamax Amidate should show a dominant mass spec peak near 1032 Da.
The differences between these compounds are not subtle at the analytical level. A 129 Da gap between 855 and 984 is the adamantane modification. A 48 Da gap between 984 and 1032 is the additional amide end-cap. Any reputable laboratory running proper LC-MS cannot confuse these three compounds.
If a COA does not specify the observed molecular mass and only shows a generic pass/fail notation, that is not adequate documentation. The listed research text specifies asking for the specific observed mass. That is standard analytical information any legitimate lab provides.
For the full breakdown of what every COA test measures and what documentation to require from any vendor, see our COA guide.
The Practical Bottom Line
N-Acetyl Semax Amidate is where readers start. Best availability, cleanest documentation, proven behavior, no sourcing landmines.
Adamax at 984 Da is the logical next step once readers know the individual response. The adamantane modification is real, the extended duration is real, and the stronger CNS penetration is real. Just verify the mass spec number on the COA before readers trust the label.
N-Acetyl Adamax Amidate at 1032 Da is theoretically the pinnacle of the family. Practically, it does not exist in the verified market right now. Monitoring is warranted, but pursuit is best deferred until the documentation infrastructure catches up.
Three compounds. One family. One shared mechanism. Three different pharmacokinetic profiles. The mass spectrometry number on the COA is the only thing that tells readers which one they actually have.
For vetted vendors carrying the Semax family with documented third-party testing including mass spectrometry identification, browse our vendor directory. And for more on the wider nootropic peptide landscape, see our Top 5 Nootropic Peptides guide.